Shares of Novartis were climbing higher on Friday after the Food and Drug Administration (FDA) approved Novartis’ $2.1 million gene therapy Zolgensma. Zolgensma is a one-time treatment for spinal muscular atrophy and is the world’s most expensive drug now. Previously Novartis had said that the treatment could cost anywhere from $1.5 to $5 million but … Continue reading “Novartis’ Gene Therapy Gets Nod from FDA”
